Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Twist Bioscience to Collaborate with Lilly's TuneLab on Antibody Drug Discovery

16 September 2026 · By · Wire by Fusion42

Published

16 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at genomeweb.com →

◆ Verified

Fusion42 · 16 September 2026 · Fusion42 review

Twist Bioscience announces a partnership with Eli Lilly's AI platform TuneLab to advance antibody drug discovery, combining synthetic DNA expertise with AI capabilities.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

AI-driven drug discovery just opened a new collaboration path combining synthetic DNA and AI; biotech founders must explore partnerships with AI platforms fast to avoid falling behind.

◆ Coverage

2 sources · 16 Sep 2026

◆ Related on Wire

◆ Topics

Biotechantibody-drug-discoveryai-partnershipbiotechdrug-development